A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies

• Status: Suspended
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to determine overall survival 180 days after transplantation involving HLA-haploidentical stem cell/bone marrow graft, and post-transplant Cy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Cyclophosphamide

Criteria

Inclusion Criteria:

1. Age: Subjects 18-70 years old.

2. Donor must be 18 years of age.

3. HLA typing will be performed at high resolution. A minimum match of 5 out of 10 is required.

4. Patients must have received multi-agent chemotherapy within 3 months of consent date (measured from the start date of chemotherapy).

5. Acute Leukemias.

• Acute Lymphoblastic Leukemia in high risk 1st complete response (CR1)

• Acute Myelogenous Leukemia in high risk 1st complete response (CR1)

• Acute Leukemias in 2nd or subsequent Complete Response (CR)

• Biphenotypic/Undifferentiated Leukemias in 1st or subsequent Complete Response (CR).

6. Burkitt's lymphoma: second or subsequent Complete Response (CR).

7. Lymphoma

8. Patients with adequate physical function

9. Performance status: Karnofsky score 70-100%.

Exclusion Criteria: